X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (216) 216
female (139) 139
male (136) 136
oncology (132) 132
middle aged (128) 128
aged (109) 109
index medicus (108) 108
adult (96) 96
hematology (94) 94
cancer (58) 58
acute myeloid leukemia (57) 57
aged, 80 and over (51) 51
leukemia, myeloid, acute - drug therapy (48) 48
acute myelogenous leukemia (45) 45
leukemia, myeloid, acute - genetics (45) 45
treatment outcome (40) 40
article (39) 39
acute myeloid-leukemia (37) 37
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
prognosis (34) 34
acute disease (32) 32
leukemia (31) 31
adolescent (26) 26
chemotherapy (26) 26
leukemia, myeloid, acute - mortality (24) 24
cell line, tumor (22) 22
cells (22) 22
hematology, oncology and palliative medicine (22) 22
karyotyping (22) 22
young adult (22) 22
disease-free survival (21) 21
expression (21) 21
retrospective studies (21) 21
care and treatment (20) 20
cytarabine - administration & dosage (20) 20
group-b (20) 20
remission induction (20) 20
therapy (20) 20
aml (19) 19
hemic and lymphatic diseases (19) 19
leukemia, myeloid, acute - pathology (19) 19
mutation (19) 19
myelodysplastic syndromes (19) 19
research (19) 19
survival (19) 19
survival rate (19) 19
abridged index medicus (18) 18
acute lymphoblastic-leukemia (18) 18
cytogenetics (17) 17
leukemia, myeloid - genetics (17) 17
pharmacology & pharmacy (17) 17
time factors (17) 17
antineoplastic agents - therapeutic use (16) 16
p-glycoprotein (16) 16
apoptosis (15) 15
translocation, genetic (15) 15
animals (14) 14
antineoplastic agents - pharmacology (14) 14
atp binding cassette transporter, sub-family g, member 2 (14) 14
colony-stimulating factor (14) 14
gene expression profiling (14) 14
genetics & heredity (14) 14
recurrence (14) 14
risk factors (14) 14
survival analysis (14) 14
acute nonlymphocytic leukemia (13) 13
age factors (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
dose-response relationship, drug (13) 13
drug-resistance (13) 13
flow cytometry (13) 13
gene (13) 13
gene expression regulation, leukemic (13) 13
kaplan-meier estimate (13) 13
multidrug resistance (13) 13
myelodysplastic syndrome (13) 13
myelodysplastic syndromes - drug therapy (13) 13
neoplasm proteins - genetics (13) 13
southwest-oncology-group (13) 13
bone marrow - pathology (12) 12
cytogenetic analysis (12) 12
drug resistance, multiple (12) 12
in situ hybridization, fluorescence (12) 12
leukemia, myeloid - pathology (12) 12
medicine & public health (12) 12
older patients (12) 12
proteins (12) 12
analysis (11) 11
atp-binding cassette transporters - metabolism (11) 11
drug resistance, neoplasm (11) 11
internal tandem duplication (11) 11
acute promyelocytic leukemia (10) 10
antineoplastic agents - adverse effects (10) 10
atp-binding cassette, sub-family b, member 1 - metabolism (10) 10
breast cancer resistance protein (10) 10
cytarabine (10) 10
diagnosis (10) 10
embryonic structures (10) 10
immunophenotyping (10) 10
leukemia, myeloid - drug therapy (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cancer Therapeutics, ISSN 1535-7163, 06/2017, Volume 16, Issue 6, pp. 991 - 1001
The receptor tyrosine kinase fms-like tyrosine kinase 3 (FLT3), involved in regulating survival, proliferation, and differentiation of hematopoietic... 
AML | POTENT INHIBITOR | INTENSIVE CHEMOTHERAPY | PTK INHIBITORS | ONCOLOGY | PROMOTES RESISTANCE | RISK MYELODYSPLASTIC SYNDROME | KINASE INHIBITOR | MUTATIONS | SORAFENIB | PHASE-I | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Leukemia, Myeloid, Acute - pathology | Humans | Protein Multimerization | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Treatment Outcome | Clinical Trials as Topic | Tandem Repeat Sequences | fms-Like Tyrosine Kinase 3 - chemistry | fms-Like Tyrosine Kinase 3 - metabolism | Leukemia, Myeloid, Acute - mortality | fms-Like Tyrosine Kinase 3 - genetics | Drug Resistance, Neoplasm - genetics | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Protein Binding | Protein Interaction Domains and Motifs | Protein Kinase Inhibitors - pharmacology | Mutation | Drug Evaluation, Preclinical | Leukemia, Myeloid, Acute - genetics | Cell proliferation | Tyrosine | Drugs | Medical research | Cell survival | Myeloid leukemia | Leukemia | Clinical trials | Kinases | Survival | Patients | Progenitor cells | Proteasome inhibitors | Hemopoiesis | Signaling | Chemotherapy | Inhibitors | Cells (biology) | Protein-tyrosine kinase receptors | Flt3 protein | Acute myeloid leukemia | Protein-tyrosine kinase | Cancer | FLT3 internal tandem duplication | FLT3 point mutation | FLT3 inhibitors | acute myeloid leukemia | resistance
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3951 - 3951
Abstract Introduction: In 30% of acute myeloid leukemia (AML) patients, internal tandem duplication of fms-like tyrosine kinase 3 (FLT3-ITD) causes... 
Journal Article
Biochemical Pharmacology, ISSN 0006-2952, 04/2012, Volume 83, Issue 8, pp. 1084 - 1103
Journal Article
Cancer Research, ISSN 0008-5472, 04/2012, Volume 72, Issue 8 Supplement, pp. 4581 - 4581
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 4736 - 4736
Journal Article
Blood, ISSN 0006-4971, 04/2003, Volume 101, Issue 8, pp. 2940 - 2954
Signal transducer and activator of transcription (STAT) proteins are a 7-member family of cytoplasmic transcription factors that contribute to signal... 
GROWTH-FACTOR RECEPTOR | JAK-STAT PATHWAY | PERIPHERAL-BLOOD CELLS | COLONY-STIMULATING FACTOR | ACUTE MYELOGENOUS LEUKEMIA | CHRONIC LYMPHOCYTIC-LEUKEMIA | TYROSINE KINASE INHIBITOR | ACUTE MYELOID-LEUKEMIA | HEMATOLOGY | DNA-BINDING ACTIVITY | CHRONIC MYELOMONOCYTIC LEUKEMIA | Granulocyte Colony-Stimulating Factor - physiology | Myeloid Cells - cytology | Neoplasms - metabolism | Trans-Activators - classification | Humans | Neoplasm Proteins - physiology | Transcriptional Activation | Neoplasm Proteins - antagonists & inhibitors | Leukemia - metabolism | Structure-Activity Relationship | STAT6 Transcription Factor | Trans-Activators - physiology | Janus Kinase 2 | Oncogene Proteins, Fusion - physiology | Protein-Tyrosine Kinases - physiology | Protein-Tyrosine Kinases - genetics | Milk Proteins | Neoplasms - genetics | Protein Isoforms - chemistry | Drug Design | Trans-Activators - genetics | Antineoplastic Agents - pharmacology | Cell Differentiation | Proto-Oncogene Proteins | Neoplasm Proteins - genetics | Leukemia - genetics | DNA-Binding Proteins - physiology | DNA-Binding Proteins - antagonists & inhibitors | Signal Transduction | Neoplasm Proteins - chemistry | Gene Expression Regulation, Leukemic | DNA-Binding Proteins - genetics | DNA-Binding Proteins - chemistry | Forecasting | Protein Isoforms - physiology | Mice, Knockout | DNA-Binding Proteins - classification | Animals | STAT5 Transcription Factor | Fusion Proteins, bcr-abl - physiology | Oncogene Proteins, Fusion - genetics | Myeloid Cells - metabolism | Mice | STAT3 Transcription Factor | Trans-Activators - antagonists & inhibitors | Protein Isoforms - genetics
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 3866 - 3866
Introduction: 
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 8, pp. 1061 - 1075
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 14, pp. 2348 - 2355
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5273 - 5273
Abstract Introduction Despite recent advances in treatment, acute myeloid leukemia (AML) remains difficult to cure with high rates of relapse.... 
Journal Article